Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "High-Grade Glioma - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This "High-grade Glioma - Pipeline Insight, 2024," report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in High-grade Glioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
High-grade Glioma Emerging Drugs Chapters
This segment of the High-grade Glioma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
High-grade Glioma Emerging Drugs
OT101: Mateon TherapeuticsOT101, a first-in-class RNA therapeutic, is designed to abrogate the immunosuppressive actions of TGF-beta 2. In a completed Phase II clinical study, OT-101 exhibited clinically meaningful single-agent activity and induced durable complete and partial responses in recurrent and refractory adult high-grade glioma patients, including adults with GBM. Further development of OT-101 may offer renewed hope for salvage therapy of pediatric DIPG patients who have this rare and fatal disease.
BMX-001: BioMimetixBMX-001 is being studied in a phase II randomized trial studying the safety and efficacy of the investigational drug in patients with newly diagnosed high-grade glioma patients who are being treated with brain radiation and temozolomide.
OKN-007: Oblato, Inc.OKN-007 is being developed by Oblato, Inc for the treatment of High-grade Glioma. It is currently in phase I/II stage of development.
PTC596: PTC TherapeuticsPTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. PTC596 acts by altering and destroying the BMI1 protein through a process called phosphorylation. PTC596 has potently inhibited BMI1 function in multiple tumor cell lines. In in vitro tests, PTC596 has preferentially targeted chemotherapy resistant cancer stem cells. Specifically, PTC596 preferentially depleted cancer stem cells in assays with tumor cell lines from fibrosarcoma, prostate and colon cancers. Conversely, the cytotoxic chemotherapies carboplatin, temozolomide, methotrexate and indibulin enriched the population of cancer stem cells in this assay. It is currently in phase I stage of development.
High-grade Glioma: Therapeutic Assessment
This segment of the report provides insights about the different High-grade Glioma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in High-grade Glioma
There are approx. 150+ key companies which are developing the therapies for High-grade Glioma. The companies which have their High-grade Glioma drug candidates in the most advanced stage, i.e. phase III include Mateon Therapeutics and others
Key Questions
- How many companies are developing High-grade Glioma drugs?
- How many High-grade Glioma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of High-grade Glioma?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the High-grade Glioma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for High-grade Glioma and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Mateon Therapeutics
- BioMimetix
- Oblato, Inc
- PTC Therapeutics
- Lee's Pharmaceutical Limited
- Nuvation Bio, Inc.
- Laminar Pharmaceuticals
- Basilea Pharmaceutica
- Aadi, LLC
- Erimos Pharmaceuticals
Key Products
- OT101
- BMX-001
- OKN-007
- PTC596
- TG02
- NUV-422
- 2-OHOA
- BAL101553
- ABI-009
- Terameprocol
Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
Molecule Type
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
High-grade Glioma Report Insights
- High-grade Glioma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
High-grade Glioma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/e21w7n
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
